ResMed Reports Q1 Fiscal 2027 Growth Driven by Manufacturing Efficiency and GLP-1 Synergy

ResMed (RMD) reported its first quarter of fiscal year 2027 results, highlighting a 7% core revenue growth and a 50 basis point expansion in gross margins. The company attributed margin improvements to supply chain efficiencies and manufacturing productivity gains, supported by facility expansions in Indiana. Management identified a significant tailwind from the rise of GLP-1 weight-loss medications, noting that patients prescribed both GLP-1s and CPAP therapy are 11% more likely to initiate sleep apnea treatment. Additionally, ResMed utilized proceeds from the sale of its noncore MatrixCare software business to return over $1 billion to shareholders through dividends and share repurchases. The company maintains a positive long-term outlook, targeting high single-digit revenue growth and earnings growth that outpaces revenue due to operational leverage. Strategic focus remains on core medical devices, digital health software, and disciplined capital allocation.

4 articles from 2 sources · updated

Coverage